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Summary A prospective, randomised controlled trial of surgery, surgery with adjuvant radiotherapy and
surgery with adjuvant chemotherapy (5-fluorouracil, adriamycin and mitomycin C) in operable gastric cancer
is described. Four hundred and thirty-six patients were randomly allocated to one of three treatment groups.
With 12 months' minimum follow-up, 334 patients have died, 292 from recurrent cancer. The median survival
for all patients was 15 months. Neither form of adjuvant therapy provides any survival advantage. Surgery
remains the principal treatment for operable gastric cancer. Care should be taken to standardise surgical
treatment and any adjuvant treatments must be compared within the confines of controlled, randomised trials.
Despite the reported decline in the incidence and death rate
from gastric cancer throughout the world (Day, 1980), it will
remain a major clinical problem for the foreseeable future.
Surgery has formed the main treatment for gastric cancer
and, as in many solid tumours, salvage therapy for unresect-
able or recurrent disease has failed to influence survival. The
Japanese have reported improved results for surgical treat-
ment of gastric cancer (Miwa, 1979), using strict rules for
surgery and pathological examination (Japanese Research
Society for Gastric Cancer 1981). In the West, however, there
has been almost no progress in the management of this
condition in recent years, and this has led to a fatalistic
attitude to treatment among many clinicians. The work from
Japan has demonstrated that progress is possible and has
shown the importance of careful documentation and auditing
both to establish the best form of surgery and to assess the
value of any adjuvant treatment.
The British Stomach Cancer Group (BSCG) designed a
prospective, randomised controlled trial to compare surgery
alone with surgery and adjuvant radiotherapy or surgery and
adjuvant chemotherapy in operable disease. The protocol
emphasised detailed recording of surgical procedures together
with full documentation and thorough review of the resected
specimen in order to stage disease accurately. The chemo-
therapy regimen comprised 5-fluorouracil (5-FU), adriamycin
and mitomycin C, a combination which in studies of
advanced disease has produced a 42% response rate (Mac-
Donald et al., 1980) and gave a 37% response rate in a pilot
study of the BSCG variant (MAF) (P.F.M. Wrigley; personal
communication).
The incorporation of adjuvant radiotherapy was based on
evidence from autopsy and re-operation series which has
consistently demonstrated that the stomach bed and regional
nodes were the most common sites of failure either alone or
in combination with distant metastases (McNeer et al., 1951;
Gunderson & Sosin, 1982). Furthermore, in selected patients
modest doses of megavoltage irradiation has improved survi-
val at 2 years when compared with a control group under-
going gastric resection only (Robinson & Cohen, 1977).
Recruitment to this trial was completed between June 1981
and July 1986. This report describes the details of this trial
and evaluates the initial results.
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Materials and methods
A prospective, randomised controlled trial of adjuvant
chemotherapy and radiotherapy following gastric resection
for adenocarcinoma recruited patients from 10 centres
throughout the United Kingdom. Participating centres were
the West Midlands, London, Manchester, Airedale, York,
Bristol, Swansea, Sunderland, Leeds and Edinburgh.
Patients eligible for entry to the trial were aged between 15
and 74 years and had undergone surgical resection for adeno-
carcinoma of the stomach. Patients were staged using a
clinicopathological system (Table I). All patients entered into
the study gave informed consent.
Those cases excluded were stage I, IVAii or IVB disease,
those who had previous significant malignant disease or prior
cytotoxic or radiation therapy. In addition, patients were
excluded from randomisation where there was any intestinal
or biliary obstruction (unrelieved by surgery), impaired renal
function (blood urea greater than 9 mmol 1' or serum
creatinine greater than 120 mmol I'), or concurrent cardiac
failure.
Before randomisation patients were stratified by centre
according to age (younger than 60 years or 60 years and
over), length of history (less than 6 months and 6 months or
longer) and stage of disease.
Randomisation was into one of three treatment groups:
surgery alone, surgery and radiotherapy to the tumour bed
Table I Staging system used
Stage Clinicopathological details
I Mucosa + ve
Submucosa + ve or -ve
Muscularis propria + ve or -ve
Serosa -ve
Nodes -ve
II Mucosa + ve
Submucosa + ve
Muscularis propria + ve
Serosa + ve
Nodes -ve
III Mucosa + ve
Submucosa + ve or -ve
Muscularis propria + ve or -ve
Serosa + ve or -ve
Nodes + ve
IVA Resectable
(i) Local residual disease
(ii) Metastatic residual disease
IVB Unresectable
(i) Locally advanced
(ii) Metastatic
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and surgery and postoperative combination cytotoxic chemo-
therapy. Randomisation was performed by the West Mid-
lands Regional Cancer Registry. Data collection and analysis
were carried out by the West Midlands Cancer Research
Campaign Clinical Trials Unit.
Participating surgeons were asked to document the macro-
scopic extent of the primary tumour and make a detailed
assessment of lymph node and other visceral involvement.
For patients undergoing curative surgery, an RI resection
was recommended. Total gastrectomy was not routinely
advocated for lesions proximal to the antrum. As a result
subtotal and proximal partial gastrectomies were included for
mid and proximal lesions respectively. Resections were
deemed palliative if low volume local disease remained (stage
IVai). More extensive, yet resectable lesions (stage IVaii)
were excluded. During the procedure, surgeons were request-
ed to mark the splenic hilum, porta hepatis and any gross
residual disease with metal clips for subsequent radiotherapy
planning.
On pathological examination the resected specimens were
measured in either the fixed or unfixed state. Macroscopic
and microscopic description of the specimen included assess-
ment of the depth of penetration and the involvement of
proximal and distal resection margins. Participating patho-
logists were asked to dissect lymph nodes from the cardia,
lesser curve, pylorus, greater curve, splenic hilum, posterior
pancreas, left gastric artery and coeliac axis and to note the
number infiltrated at each site. Any involvement of other
resected organs was recorded. A central pathology panel
reviewed the sections from resected specimens and classified
them according to both the World Health Organization and
Lauren classifications.
The chemotherapy regimen consisted of mitomycin C
4 mg m-2, adriamycin 30 mg m-2 and 5-fluorouracil
600mg m2 given intravenously on one day only (MAF).
The first course was to be administered within 4 weeks of
surgery and repeated at 3-weekly intervals for a total of eight
courses. Dosages were modified according to haematological
and biochemical parameters including urinalysis for protein-
uria. Half doses were given if the white blood cell count was
in the range 2.0-3.0 x 1091' or the platelet count was
100-125 x 1091-'. If the counts were below the lower limits
of these ranges, no drugs were given and blood counts were
checked weekly until adequate levels returned. Proteinuria on
two successive occasions or a rise in blood urea to
8 mmol 1' or serum creatinine to 150 mmol 1' were indica-
tions to stop administration of mitomycin C.
Patients randomised to radiotherapy were required to
undergo intravenous pyelography, and be planned on either a
simulator or a diagnostic X-ray unit. Radiotherapy was ad-
ministered using AP/PA parallel opposed portals to include
the porta hepatis and splenic hilum as marked at surgery.
Appropriate renal shielding was employed to exclude as
much renal tissue from the treatment field as possible. A mid
line tumour dose of 4,500 cGy in 25 fractions over 35 days
was given using megavoltage equipment (cobalt-60 or linear
accelerator). A further boost dose of 500cGy to a reduced
field could be given at the discretion of the radiotherapist.
Blood counts were monitored weekly throughout treatment.
All patients were to be seen every 3 weeks for the first 6
months after surgery. Thereafter follow-up was to be every 6
weeks for 2 years and subsequently at 3-monthly intervals.
At each visit data sheets were completed to document clinical
progress, including evidence of recurrence. Haematological
and biochemical parameters were recorded together with
details of any side-effects from treatment. Clinicians were
requested to provide post mortem evidence of disease status
at death whenever possible.
Survival has been taken as the only criterion of response.
In addition to the clinical follow-up within the trial, the
completeness of the notification of death was verified by the
registration of patients with the West Midlands Regional
Cancer Registry. All randomised patients were included in
the survival analysis. The survival of live patients was cen-
sored at I July 1987 when all had complete follow-up. The
probability of survival has been estimated by the life-table
method (Kaplan & Meier, 1958) and statistical comparisions
made with the log rank test (Peto et al., 1977).
Results
Patients
During the 5 years of recruitment 436 patients were entered
into the study. The data were analysed when there was a
minimum follow-up of 12 months. After randomisation there
were 145 in the surgery only group, 153 in the radiotherapy
group and 138 in the chemotherapy group. The distribution
of patient characteristics within each treatment group is
shown in Table II.
After completion of recruitment, the eligibility of all
patients was assessed according to the protocol criteria for
inclusion in the trial. Details of the 25 entry criteria viola-
tions found are shown in Table III.
Six patients died within 30 days of operation. Three died
of their disease, one of a myocardial infarct and two of
complications of surgery. All had already been randomised,
to surgery alone (one patient), radiotherapy (two patients)
and chemotherapy (three patients).
Randomisation was achieved within a month of operation
in 409 (95%) of the 436 patients entered. The median time to
randomisation was 13 days with a range of 1-82 days. The
time from operation to start of treatment varied with the
treatment drawn. The 145 patients in the surgery group were
placed on routine review with 49 (34%) being seen in the first
month and 66 (46%) being seen in the second. For the 153
patients randomised to radiotherapy 31 (20%) began radio-
therapy within 1 month of operation and 60 (39%) within
the second. By comparision 74 (54%) of the 138 randomised
to chemotherapy were treated in the first month and 37
(27%) in the second. Treatment commenced within a month
of operation in 105 (45%) of the 232 cases who received
adjuvant therapy.
Treatment
Chemotherapy The number of cycles given to each of the
138 patients randomised to receive chemotherapy is shown in
Table IV. Twenty-three (17%) patients did not receive
chemotherapy. They either refused (11 patients), were too ill
or had died (9 patients) or had pre-existing cardiac disease (2
patients). In one case the reason is not known.
Thirty patients (22%) received less than six cycles of
chemotherapy. In this group, progressive ill health (13
patients) and refusal (12 patients) were the major reasons for
stopping. The remaining indications were debilitating vomit-
ing and nausea (3 patients), haematological and biochemical
toxicity (I patients) and hypotension (1 patient).
Eight-five (62%) of the 138 patients completed six or more
cycles with 58 (42%) completing the planned eight cycles. In
the 27 patients having six to seven cycles, seven patients
became too unwell and two refused to continue the final
cycles. Side-effects halting treatment were haematological and
biochemical toxicity (7 patients), debilitating nausea and
vomiting (2 patients) and allergy to one of the agents (6
patients). Hypotension caused one patient to stop and in two
patients the reason for failure to complete the treatment
programme is not known.
The indications for the modification of chemotherapy have
already been described. Of the 115 who started treatment, 75
completed their given cycles without dose modification. The
commonest reasons for modification were haematological
changes (19 patients) and evidence of renal dysfunction (10
patients). The remaining reasons and cycle at which dose
modifications were made are shown in Table V.
Radiotherapy One hundred and seventeen patients of the
153 randomised to radiotherapy received treatment. Nineteen
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Table II Patient characteristics by treatment group
Treatment group
Surgery Radiotherapy MAF All
(n = 145) (n = 153) (n = 138) patients
Continuous data
Age (years)a 63 65 63 64
Duration of symptoms (months)a 5 5 5 5
Weight loss (as % of normal weight)' 10 10 10 10
Categorical data
Sex n % n % n % n %
Male 106 73 99 65 98 71 303 69
Female 39 27 54 35 40 29 133 31
Stage
II 26 18 25 16 22 16 73 17
III 76 52 83 54 76 55 235 54
IVAi 43 30 45 29 40 29 128 29
Serosal involvement 135 93 141 92 120 87 396 91
Node involvement 110 76 122 80 103 75 335 77
Resection line involvement 23 16 27 18 28 20 78 18
Residual disease present 35 24 33 22 25 18 93 21
Resection
Radical (RI) 125 86 129 84 119 86 373 86
Palliative 20 14 24 16 19 14 63 14
aMedian values.
Table III Protocol violations by treatment group
Surgery Radiotherapy Chemotherapy Total
Too old 1 1 2
Histologya 1(NH lymphoma) 1(NH lymphoma) l(Carcinoid) 3
Prior malignancyb 1 3 - 4
Cardiac diseasec - - 2 2
Stage I - 1 2 3
Stage IVAii 5 4 2 11
Total 7 10 8 25
aNot gastric adenocarcinoma on review. bOne cervix carcinoma, one melanoma, one
rectum carcinoma, one bladder papilloma. cNot assessable in other groups.
Table IV Numbers of patients according to chemotherapy cycles
received
Number ofcycles Number ofpatients %
0 23 17
1 6 4
2 6 4
3 5 4
4 10 7
5 3 2
6 13 9
7 14 11
8 58 42
Total 138 100
general condition and 13 patients refused to start radio-
therapy. Four patients who failed to fulfil the entry criteria
(two stage IVAii, one too old, one lymphoma) were
unsuitable to start treatment.
The protocol defined dose of 4,500cGy (+10%) was ad-
ministered in 102 patients. Two patients received the addi-
tional 500cGy boost dose to a reduced field. In 13 patients
lesser doses were given. One centre elected to vary from the
protocol by giving 3,700cGy (± 10%) in 16 fractions over 21
days (8 patients). Poor condition or progression of disease
caused a dose reduction of more than 10% in four patients,
and gastrointestinal toxicity required a dose reduction in one
patient.
Symptomatic side-effects were recorded for all patients on
radiotherapy. In 55 cases no side-effects were seen. Mild
nausea and vomiting occurred in 48 patients, and was severe
in one further patient. A low white blood count was
documented in two patients. Desquamation in the treated
area was reported in five cases. Poor tolerance due to poor
general condition was seen in six cases.
Table V Time of first dose modification by cause
Cycle number
Cause of
modification 1 2 3 4 5 6 7 8 Total
Haematology - 4 1 4 2 1 6 1 19
Urea 2 2 2 1 1 - 2 - 10
Allergy - - - - 2 2 - - 4
Cardiac 1 - - 3 - - - - 4
Vomiting/nausea - - - - - - - I I
Hypotension I 1
Reason not known - - - - 1 - - - I
Total 3 6 4 8 6 3 8 2 40
Survival
The median duration of survival was 15 months. Stage had a
significant influence on survival (Figure 1), but there was no
significant effect for the other stratification variables (age
X2 = 0.01, P = 0.94; duration of symptoms X21 = 0.49,
P = 0.49; centre X27 = 4.0, P = 0.79).
Effect oftreatment
The three treatment groups do not differ significantly in their
survival (Figure 2; X22 = 5.3, P = 0.07). Neither the chemo-
therapy group (X21 = 0.8, P = 0.36) nor the radiotherapy
group (X21 = 1.8, P = 0.18) differ from the control group.
Details of the site and date of first recurrence have been
recorded in 172 cases. These data are largely based on
clinical findings made at routine follow up. Further investi-
gations performed in this group included nine second look
laparotomies. The site of recurrence has been classified as
local to the gastric bed or regional nodes, distant metastasis742 W.H. ALLUM et al.
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Number of patients
At risk
Stage II
Stage III
Stage IVAi
Stage 11
Stage III
I Stage IVAi
2 Months
73 61 47 33 21 17
235 142 78 50 31 19
128 48 14 8 -
Figure 1 Survival by stage (stage II, 39/73 deaths; stage III, 175/235 deaths; stage IVAi, 120/128 deaths; X22 <0.0001, P = 72.3).
C
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Chetmiotherapy(M)
0 1 2 24 36 48 60
145
153
138
82
79
90
45
43
48
31
26
34
17
13
20
13
9
18
Figure 2 Survival by treatment group (surgery group, 110/145 deaths; radiotherapy group, 123/153 deaths; chemotherapy group,
101/138 deaths; X22 = 5.3, P = 0.07).
or both (Table VI). These data, though based on clinical
findings, show a lower local and regional relapse rate in those
receiving adjuvant treatment (X2 = 10.7, P<0.01).
Table VI Site of first recurrence by treatment group
Surgery Radiotherapy Chemotherapy Total
Local/regional 37 14 21 72
Distant 30 29 33 92
Both 2 1 5 8
Total 69 44 59 172
Table VII Cause of death by treatment group
Surgery Radiotherapy Chemotherapy Total
Cancer 101 102 89 292
Complications 0 2 4 6
Second primary 1 4 2 7
Othera 7 12 5 24
Cause unknown 1 3 1 5
Total 110 123 101 334
aFour had recurrent disease present at death.
Cause ofdeath
At the time of analysis 334 (77%) of the patients admitted to
the trial had died, 110 in the surgery alone group, 123 in the
radiotherapy group and 101 in the chemotherapy group. The
cause of death (Table VII) has been obtained from the
clinican in charge of the case, general practitioners or from
cancer registries. Autopsies were performed on 35 (11%).
Two hundred and ninety-two deaths were due to recurrent
stomach cancer. Other causes were responsible for the death
of 37 patients. Seven patients died from other primary
cancers, of which three were bronchogenic, and one each of
melanoma, larynx, prostate and colon. Fourteen deaths were
secondary to cardiovascular or cerebrovascular disease. This
group includes seven acute myocardial deaths, six of which
occurred in the radiotherapy group. General deterioration in
health caused 10 deaths. Six patients died as a result of
surgical complications, one of which followed a second gast-
ric resection for recurrent disease. The cause of death is not
known in five cases.
In summary, 37 patients are known to have died from
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causes other than gastric cancer, eight of whom were ran-
domised to surgery alone, 18 to radiotherapy and 11 to
chemotherapy. This difference in the proportion of non-
cancer deaths between the three treatment groups is not
statistically significant (X2 = 3.5, 0.1 <P <0.2).
Discussion
The study described in this report was set up to evaluate the
role of two modalities of adjuvant treatment in advanced
gastric cancinoma. The trial was designed to incorporate the
detailed documentation recommended by Japanese workers
and was extended to include a central pathology review. A
detailed record of the surgical procedures undertaken in each
patient was made and all histological specimens obtained at
operation were subjected to thorough review to ensure con-
sistent pathological grading and staging. The adjuvant treat-
ments assessed were short-term chemotherapy using the most
effective agents in combination and local radiotherapy to the
tumour bed. In this interim report the results of recruitment,
randomisation and the therapeutic regimens have been pre-
sented. The clinicopathological data will form the subject of
a future report.
The cytotoxic agents evaluated in this study have been
reported to have produced the best response rates seen in the
treatment of advanced or recurrent gastric cancer (Earl et al.,
1984). There is no doubt that response rates in advanced
disease are important indicators of sensitivity to cytoxic
agents. However, careful review of the reports of these
studies demonstrate very few complete and durable res-
ponses. Indeed one of the larger studies, using 5-FU,
adriamycin and mitomycin C, documents only two complete
responses lasting for 23 and 29 months respectively
(Cunningham et al., 1984).
The results of this study demonstrate that partial response
rates produced by these agents fail to translate into a survival
advantage in an adjuvant setting. In a report of a similar
study evaluating the same three cytotoxic agents, but at
different doses, the preliminary results demonstrate a modest
early survival advantage for the treated group (Schein et al.,
1986). It remains to be seen whether this advantage will
persist.
There have been reports of complete responses to
radiotherapy given as palliation for advanced disease
(Gunderson & O'Connell, 1984; Weiland & Hymmen, 1970),
though these are rare. The difficulties in the use of
radiotherapy in the treatment ofgastric cancer stem from the
sensitivity of the surrounding structures which limit the dose
that can be used (Gunderson, 1986). Studies have demon-
strated that the sites of local failure can be encompassed in a
conventional radiotherapy field (Gunderson & Sosin, 1982).
Using such a field, the interim results of this study demon-
strate no influence on survival from the use of adjuvant
radiotherapy.
Adjuvant therapy aimed at treating microscopic or macro-
scopic disease may theoretically result in prolongation of
survival. It is evident that eradication of large volumes of
modestly sensitive tumours by cytotoxics may now be con-
sidered optimistic if not naive. Models of tumour growth
indicate that tumours are most rapidly dividing when small
in volume (Carter et al., 1988) and most cytotoxic agents act
optimally on the dividing cells. The timing of adjuvant
therapy in those with microscopic disease may be crucial.
This has been demonstrated in breast cancer (Nissen-Meyer
et al., 1978) and gastric cancer (Imanaga & Nakazato, 1977;
Nakajima et al., 1978). Treatment in the perioperative period
when tumour burden is minimal may provide the means to
improve on results with currently available agents.
Large multicentre studies such as the one reported here
and its predecessor (Allum et al., 1989) demonstrate how
groups of clinicans can execute complex chemotherapy
schedules and also undertake close review of the effects of
such treatment. However, such studies equally demonstrate
the difficult logistics of adherence to protocols. The first trial
had demonstrated a significant improvement in survival at
1 year for those treated in the first month (Fielding et al.,
1983). The aim in this second sti dy was to commence
therapy within a month of surgery. Tais was achieved in only
45% of patients who received adjuvant treatment. This must
in part reflect the scheduling of radiotherapy machine time
and the variable postoperative recovery of patients.
The other major problem encountered in this study was
inability to complete the treatment schedules. Only 62% of
those randomised to chemotherapy completed six or more of
the recommended eight cycles. The major reasons for failure
to complete chemotherapy were early death and progressive
disease with toxicity having a minor role. In the radiotherapy
group, there was closer adherence to the recommended treat-
ment, with 104 of the 117 who started treatment receiving the
correct dose. Little significant toxicity was seen in the
radiotherapy group, with dose reduction due to toxicity in
only one patient. However, a large number (24%) failed to
start radiotherapy as randomised. Again, ill health and early
death prevented patients from starting treatment. No patient
in this trial suffered severe, life threatening toxicity as a result
of either adjuvant treatment.
Deviations from the protocol become more important
when the effect of treatment is considered. In addition the
difficulty of establishing the precise site and time of recur-
rence has led to survival being taken as the only determinant
of response in this study. However, the clinical information
that is available for a number of patients suggests that the
distribution of recurrence may be altered by the adjuvant
modalities. Local control was apparently improved in those
treated by irradiation or chemotherapy; however, as the site
of recurrence cannot be evaluated for all patients stated to
have died with disease, these data must be viewed with
caution.
The results of the present study have failed to provide any
evidence that the adjuvant therapies evaluated influence sur-
vival. The use of adjuvant treatment in this disease should be
restricted to randomised, controlled trials where their effect
can be properly assessed.
In gastric cancer, surgery at an early stage remains the
goal. Unfortunately most patients in the United Kingdom
currently present with disease which is not confined to the
stomach. Standardisation of surgical precedure and
documentation of operative and pathological findings are of
paramount importance in order to compare the results of
adjuvant regimens. This second trial attempted to address
this problem in an open, multicentre setting. The Medical
Research Council are currently undertaking a randomised
trial to evaluate surgical techniques in cases with curable
disease. It is only by such critical evaluation of treatment
that progress is likely in this disease and in the other com-
mon solid tumours in which little improvement in prognosis
has been seen over the past 20 years.
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